MA43288A1 - Procédés de production et formes cristallines d'un inhibiteur mdm2 - Google Patents

Procédés de production et formes cristallines d'un inhibiteur mdm2

Info

Publication number
MA43288A1
MA43288A1 MA43288A MA43288A MA43288A1 MA 43288 A1 MA43288 A1 MA 43288A1 MA 43288 A MA43288 A MA 43288A MA 43288 A MA43288 A MA 43288A MA 43288 A1 MA43288 A1 MA 43288A1
Authority
MA
Morocco
Prior art keywords
production processes
crystal forms
mdm2 inhibitor
intermediates
chlorophenyl
Prior art date
Application number
MA43288A
Other languages
English (en)
Other versions
MA43288B1 (fr
Inventor
Matthew Bio
Sebastien Caille
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43288(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA43288A1 publication Critical patent/MA43288A1/fr
Publication of MA43288B1 publication Critical patent/MA43288B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

La présente invention concerne des procédés de production d'acide 2-((3r,5r,6s)-5-(3- chlorophényl)-6- (4-chlorophényl)-l-((s)-l-(isopropylsulfonyl)-3-méthylbutan-2-yl)-3- méthyl-2-oxopipéridin-3-yl)acétique ainsi que des intermédiaires et des procédés de production des intermédiaires. L'invention concerne également des formes cristallines du composé et les intermédiaires.
MA43288A 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2 MA43288B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10

Publications (2)

Publication Number Publication Date
MA43288A1 true MA43288A1 (fr) 2020-04-30
MA43288B1 MA43288B1 (fr) 2020-10-28

Family

ID=51063849

Family Applications (3)

Application Number Title Priority Date Filing Date
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2

Country Status (37)

Country Link
US (10) US9376386B2 (fr)
EP (2) EP3008039B1 (fr)
JP (4) JP6998655B2 (fr)
KR (3) KR20210121270A (fr)
CN (3) CN110627708A (fr)
AP (1) AP2015008891A0 (fr)
AR (2) AR096582A1 (fr)
AU (5) AU2014278428B2 (fr)
BR (2) BR122020003153B1 (fr)
CA (4) CA3201958A1 (fr)
CL (3) CL2015003589A1 (fr)
CR (2) CR20210290A (fr)
CY (1) CY1123661T1 (fr)
DK (1) DK3008039T3 (fr)
EA (3) EA201891642A1 (fr)
ES (1) ES2851023T3 (fr)
HR (1) HRP20202065T1 (fr)
HU (1) HUE053047T2 (fr)
IL (4) IL297860A (fr)
JO (2) JOP20200296A1 (fr)
LT (1) LT3008039T (fr)
MA (3) MA53572A1 (fr)
MX (2) MX2015016856A (fr)
MY (1) MY194848A (fr)
NZ (1) NZ714821A (fr)
PE (2) PE20160113A1 (fr)
PH (1) PH12015502705A1 (fr)
PL (1) PL3008039T3 (fr)
PT (1) PT3008039T (fr)
RS (1) RS61192B1 (fr)
SG (2) SG10201801402XA (fr)
SI (1) SI3008039T1 (fr)
TN (1) TN2015000521A1 (fr)
TW (3) TWI698428B (fr)
UA (1) UA121301C2 (fr)
UY (1) UY35605A (fr)
WO (1) WO2014200937A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2013049250A1 (fr) 2011-09-27 2013-04-04 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014151863A1 (fr) 2013-03-14 2014-09-25 Amgen Inc. Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX2020013670A (es) 2013-11-11 2022-09-30 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
KR20210019422A (ko) * 2018-04-30 2021-02-22 카토스 테라퓨틱스, 인크. 암 치료 방법
EP3801476A4 (fr) * 2018-05-25 2022-07-06 Kartos Therapeutics, Inc. Méthodes de traitement des néoplasmes myéloprolifératifs
KR20210052497A (ko) * 2018-08-31 2021-05-10 암젠 인크 Mdm2 억제제의 제조 방법
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021236474A1 (fr) * 2020-05-22 2021-11-25 Merck Sharp & Dohme Corp. Nouveaux procédés de préparation de conjugués de la protéine il-2
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023014160A1 (fr) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 Forme cristalline de phénylcarbamate et son procédé de préparation
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
WO2023039161A1 (fr) * 2021-09-09 2023-03-16 Kartos Therapeutics Procédés de traitement du cancer dépendant de l'expression du gène myc
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
WO1995023135A1 (fr) 1991-03-07 1995-08-31 Fisons Corporation Derives de diphenyl-2-piperidinone et -2-pyrrolidinone possedant une activite anticonvulsivante et neuroprotectrice
EP1186603A3 (fr) 1994-08-19 2003-07-09 Abbott Laboratories Procédés de préparation d'antagonistes de l'endotheline
WO1997030045A1 (fr) 1996-02-13 1997-08-21 Abbott Laboratories Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
SK1452000A3 (en) 1997-08-04 2001-05-10 Abbott Lab Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
WO1999031507A1 (fr) 1997-12-18 1999-06-24 Eli Lilly And Company Banques combinatoires sur la base de matrices peptidomimetiques
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (fr) 2000-08-31 2002-03-07 Abbott Laboratories Antagonistes de l'endotheline
WO2002042731A2 (fr) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Procedes et dispositifs pour une cristallisation a haut debit
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
EP1408986B1 (fr) 2001-05-08 2008-09-24 Yale University Composes proteomimetiques et procedes correspondants
EP1395560A1 (fr) 2001-05-23 2004-03-10 Ucb, S.A. Derives d'acide alcanoique 2-oxo-piperidinyl- et 2-oxo-azepanyle destines au traitement de l'epilepsie et d'autres troubles neurologiques
AU2002366278B2 (en) 2001-12-18 2007-07-19 F. Hoffmann-La Roche Ag CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
KR20110033964A (ko) 2004-05-18 2011-04-01 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) * 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
EA012181B1 (ru) 2004-10-18 2009-08-28 Амген, Инк. Соединения тиадиазола и их применение
MX2007010054A (es) 2005-02-18 2007-09-21 Mitsubishi Pharma Corp Sal de un derivado de prolina, solvato de la misma y metodo de produccion de la misma.
KR20100031783A (ko) 2005-03-16 2010-03-24 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의 그의 용도
US20090131480A1 (en) 2005-04-04 2009-05-21 Eisai Co., Ltd. Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia
EP1888120B1 (fr) * 2005-06-07 2012-12-05 Ramot at Tel Aviv University Ltd. Nouveaux sels de medicaments psychotropes conjugues et leurs procedes de preparation
WO2007015929A2 (fr) * 2005-07-27 2007-02-08 University Of Toledo Analogues d'epothilone
RU2442779C2 (ru) 2005-12-01 2012-02-20 Ф. Хоффманн-Ля Рош Аг Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств
EP1981884B1 (fr) 2006-01-18 2012-06-13 Amgen, Inc Composés thiazoliques comme inhibiteurs de protéine kinase b
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
CA2657034A1 (fr) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Dicetoacides de pyridinone : inhibiteurs de la replication du vih dans une therapie combinee
WO2008021339A2 (fr) 2006-08-15 2008-02-21 Wyeth Pyrrolidine et dérivés associés utiles en tant que modulateurs des récepteurs de la progestérone
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
JP2010522177A (ja) 2007-03-23 2010-07-01 アムジエン・インコーポレーテツド 複素環化合物およびその使用
EA017389B1 (ru) 2007-03-23 2012-12-28 Амген Инк. Гетероциклические соединения и их применение
PT2139882E (pt) 2007-03-23 2014-01-30 Amgen Inc Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k)
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (fr) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Antagonistes p53/mdm2/mdm4 sélectifs et à action double
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (fr) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
CA2693473A1 (fr) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activite de pkb
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
WO2009047161A1 (fr) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Cis-imidazolines chirales
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
JP5520831B2 (ja) 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
JP2011507799A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇のためのａｍｐａ受容体アンタゴニストおよびゾニサミド
WO2009114950A1 (fr) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Composés de pyrrolidine et de pipéridine substitués, leurs dérivés et procédés de traitement de la douleur
ES2474147T3 (es) 2008-05-30 2014-07-08 Amgen, Inc Inhibidores de PI3 cinasa
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (fr) * 2008-09-10 2010-03-18 Achaogen, Inc. Analogues d’aminoglycosides antibactériens
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
CN102159207B (zh) 2008-09-18 2015-02-04 霍夫曼-拉罗奇有限公司 取代的吡咯烷-2-甲酰胺类
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2398791A1 (fr) 2009-02-18 2011-12-28 Amgen, Inc Composés d'indole ou benzimidazole convenant comme inhibiteurs de la kinase mtor
CA2755285C (fr) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibiteurs de pi3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
AU2010249040B2 (en) 2009-05-13 2013-08-22 Amgen Inc. Heteroaryl compounds as PIKK inhibitors
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
CA2765819A1 (fr) 2009-06-25 2010-12-29 Amgen Inc. Composes heterocycliques et leurs utilisations en tant qu'inhibiteurs de l'activite p13 k
US8754089B2 (en) 2009-06-25 2014-06-17 Amgen Inc. Heterocyclic compounds and their uses
AR077267A1 (es) 2009-06-25 2011-08-17 Amgen Inc Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
IN2012DN01693A (fr) 2009-08-26 2015-06-05 Novartis Ag
EP2486044A2 (fr) * 2009-10-09 2012-08-15 Achaogen, Inc. Analogues d'aminoglycoside antibactériens
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
TW201137923A (en) * 2010-02-10 2011-11-01 Halcyon Molecular Inc Aberration-correcting dark-field electron microscopy
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
KR101875720B1 (ko) * 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
TW201311938A (zh) * 2011-04-28 2013-03-16 Otsuka Chemical Co Ltd 偶氮二甲醯胺之新穎製造法
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
WO2013049250A1 (fr) 2011-09-27 2013-04-04 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
WO2014151863A1 (fr) 2013-03-14 2014-09-25 Amgen Inc. Composés morpholinone d'acide hétéroaryle utilisés comme inhibiteurs de mdm2 pour le traitement du cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
JO3768B1 (ar) 2021-01-31
IL281807B2 (en) 2023-04-01
US9623018B2 (en) 2017-04-18
AU2014278428A1 (en) 2015-11-26
KR20210121270A (ko) 2021-10-07
US20180092898A1 (en) 2018-04-05
MX2019012007A (es) 2019-11-11
LT3008039T (lt) 2021-01-25
US9801867B2 (en) 2017-10-31
TN2015000521A1 (en) 2017-04-06
AU2022271425B2 (en) 2024-06-13
MY194848A (en) 2022-12-19
UY35605A (es) 2015-01-30
TWI649306B (zh) 2019-02-01
PH12015502705B1 (en) 2016-03-14
IL297860A (en) 2023-01-01
AU2022271425A1 (en) 2022-12-22
PH12015502705A1 (en) 2016-03-14
IL281807A (en) 2021-05-31
KR20230019216A (ko) 2023-02-07
US20220280496A1 (en) 2022-09-08
TW202035370A (zh) 2020-10-01
IL266504A (en) 2019-07-31
CL2019000056A1 (es) 2019-05-03
CA2914723C (fr) 2021-06-15
MX2015016856A (es) 2016-04-07
CA3200532A1 (fr) 2014-12-18
AU2014278428B2 (en) 2018-11-15
IL266504B (en) 2021-04-29
CA3201958A1 (fr) 2014-12-18
PL3008039T3 (pl) 2021-04-19
AR096582A1 (es) 2016-01-20
AU2020267169B2 (en) 2022-08-25
CR20160010A (es) 2016-02-04
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
EP3805232A1 (fr) 2021-04-14
TWI698428B (zh) 2020-07-11
US20160289243A1 (en) 2016-10-06
IL242622A0 (en) 2016-02-01
CR20210290A (es) 2021-07-23
PE20160113A1 (es) 2016-03-03
JOP20200296A1 (ar) 2017-06-16
EA201891642A1 (ru) 2019-08-30
SG10201801402XA (en) 2018-04-27
US20160287570A1 (en) 2016-10-06
BR122020003153B1 (pt) 2022-09-27
TW201922705A (zh) 2019-06-16
SG11201509896VA (en) 2016-01-28
US20160264526A1 (en) 2016-09-15
CA2914723A1 (fr) 2014-12-18
AU2018260844B2 (en) 2020-08-13
EA202091612A1 (ru) 2020-10-05
TWI791153B (zh) 2023-02-01
CN105358530A (zh) 2016-02-24
CL2015003589A1 (es) 2016-06-17
JP2020147573A (ja) 2020-09-17
PE20210153A1 (es) 2021-01-26
AP2015008891A0 (en) 2015-11-30
AU2024216533A1 (en) 2024-09-19
US20160289178A1 (en) 2016-10-06
BR112015031004B1 (pt) 2022-09-20
IL281807B (en) 2022-12-01
AU2018260844A1 (en) 2018-11-22
HRP20202065T1 (hr) 2021-02-19
AU2020267169A1 (en) 2020-12-03
US20200281912A1 (en) 2020-09-10
MA53572A1 (fr) 2021-10-29
UA121301C2 (uk) 2020-05-12
JP2023089126A (ja) 2023-06-27
HUE053047T2 (hu) 2021-06-28
EP3008039B1 (fr) 2020-11-11
CL2021000566A1 (es) 2021-09-03
EA031254B1 (ru) 2018-12-28
JP2021130685A (ja) 2021-09-09
DK3008039T3 (da) 2021-01-04
US20140364455A1 (en) 2014-12-11
US20160289190A1 (en) 2016-10-06
US9855259B2 (en) 2018-01-02
BR112015031004A2 (pt) 2020-05-12
SI3008039T1 (sl) 2021-03-31
NZ753956A (en) 2020-12-18
CA3115609C (fr) 2023-08-08
ES2851023T3 (es) 2021-09-02
EP3008039A1 (fr) 2016-04-20
IL242622B (en) 2019-06-30
WO2014200937A1 (fr) 2014-12-18
MA43288B1 (fr) 2020-10-28
US9757367B2 (en) 2017-09-12
JP6891322B2 (ja) 2021-06-18
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
AR119727A2 (es) 2022-01-05
US9376386B2 (en) 2016-06-28
CA3115609A1 (fr) 2014-12-18
PT3008039T (pt) 2021-01-13
NZ714821A (en) 2020-10-30
JP2016528179A (ja) 2016-09-15
CN110627708A (zh) 2019-12-31
EA201592305A1 (ru) 2016-05-31
JP7263439B2 (ja) 2023-04-24
CN110003092A (zh) 2019-07-12
US20230301974A1 (en) 2023-09-28
JP6998655B2 (ja) 2022-02-04
CY1123661T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
MA43288A1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2014028597A3 (fr) Composés indazole et indole à substitution cyclohexyl et 3-cyclohexenyl
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
TW200736247A (en) Compounds for the treatment of inflammatory disorders
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
MA37650A1 (fr) Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
UA110802C2 (uk) Моногідрат похідного азаадамантану
EA201071367A1 (ru) Соли соединений ингибиторов вич
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
EA201170481A1 (ru) Сокристаллы
EP4282973A3 (fr) Procédés de préparation pour dérivés de pyrmidinecyclopentane
IN2013MU00916A (fr)
EA202190632A1 (ru) Способы получения ингибитора mdm2
MX361764B (es) Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
MX2014002343A (es) Inhibidores de parp.
IN2013MU02719A (fr)
IN2013MU02793A (fr)